Emapticap pegol(Emapticap pegol) - 药物靶点：CCL2_在研适应症：眼部疾病_专利_临床

概要

基本信息

药物类型

适配体

别名

靶点

CCL2

作用机制

CCL2抑制剂(C-C基序趋化因子-2抑制剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 29275743

来源: *****

关联

7

项与 Emapticap pegol 相关的临床试验

EUCTR2011-005710-11-CZ / Not yet recruitingN/A

A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuria.

开始日期2012-06-29

申办/合作机构

NOXXON Pharma AG

EUCTR2011-005710-11-PL / Not yet recruitingN/A

A phase IIa study to characterize the effects of CCL2 inhibition with the Spiegelmer® NOX-E36 in patients with type 2 diabetes mellitus and albuminuria.

开始日期2012-05-07

申办/合作机构

NOXXON Pharma AG

NCT01547897 / Completed临床2期

A Phase IIa Study to Characterize the Effects of CCL2 Inhibition With the Spiegelmer® NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria

Primary objective:
- To characterize the effects of 12 weeks treatment with study drug on albumin-creatinine ratio (ACR) in patients with type 2 diabetes and albuminuria
Secondary objectives:
To characterize the effect of study drug on glycosylated hemoglobin fraction (HbA1c)
To evaluate the effect of study drug on markers of glycemic disorders, systemic inflammation, renal and liver disease and cardiovascular function
To assess the safety and tolerability of study drug
To determine the population pharmacokinetics (PK) of study drug

开始日期2012-03-01

申办/合作机构

TME Pharma NV

100 项与 Emapticap pegol 相关的临床结果

登录后查看更多信息

100 项与 Emapticap pegol 相关的转化医学

登录后查看更多信息

100 项与 Emapticap pegol 相关的专利（医药）

登录后查看更多信息

4

项与 Emapticap pegol 相关的文献（医药）

2016-09-01·Expert Opinion on Investigational Drugs2区 · 医学

Targeting inflammation in diabetic kidney disease: early clinical trials

2区 · 医学

Review

作者: Sanz, Ana Belen ; Perez-Gomez, Maria Vanessa ; Zheng, Binbin ; Fernandez-Fernandez, Beatriz ; Ortiz, Alberto ; Ruiz-Ortega, Marta ; Sanchez-Niño, Maria Dolores ; Martín-Cleary, Catalina

INTRODUCTIONThe age-standardized death rate from diabetic kidney disease increased by 106% from 1990 to 2013, indicating that novel therapeutic approaches are needed, in addition to the renin-angiotensin system (RAS) blockers currently in use. Clinical trial results of anti-fibrotic therapy have been disappointing. However, promising anti-inflammatory drugs are currently on phase 1 and 2 randomized controlled trials.AREAS COVEREDThe authors review the preclinical, phase 1 and 2 clinical trial information of drugs tested for diabetic kidney disease that directly target inflammation as a main or key mode of action. Agents mainly targeting other pathways, such as endothelin receptor or mineralocorticoid receptor blockers and vitamin D receptor activators are not discussed.EXPERT OPINIONAgents targeting inflammation have shown promising results in the treatment of diabetic kidney disease when added on top of RAS blockade. The success of pentoxifylline in open label trials supports the concept of targeting inflammation. In early clinical trials, the pentoxifylline derivative CTP-499, the CCR2 inhibitor CCX140-B, the CCL2 inhibitor emapticap pegol and the JAK1/JAK2 inhibitor baricitinib were the most promising drugs for diabetic kidney disease. The termination of trials testing the anti-IL-1β antibody gevokizumab in 2015 will postpone the evaluation of therapies targeting inflammatory cytokines.

2015-01-01·Drug Discovery Today2区 · 医学

Turning mirror-image oligonucleotides into drugs: the evolution of Spiegelmer® therapeutics

2区 · 医学

Review

作者: Klussmann, Sven ; Vater, Axel

Spiegelmers are synthetic target-binding oligonucleotides built from non-natural l-nucleotides. Like aptamers, Spiegelmers fold into distinct shapes that bind the targets with high affinity and selectivity. Furthermore, the mirror-image configuration confers plasma stability and immunological passivity. Various Spiegelmers against pharmacologically attractive targets were shown to be efficacious in animal models. Three Spiegelmer candidates: emapticap pegol (NOX-E36; anti-CCL2), olaptesed pegol (NOX-A12; anti-CXCL12) and lexaptepid pegol (NOX-H94; anti-hepcidin), underwent regulatory safety studies, demonstrated good safety profiles in healthy volunteers and were taken into Phase IIa studies in patients. Proof-of-concept for emapticap pegol has recently been demonstrated in diabetic nephropathy patients. Furthermore, promising interim Phase IIa data of olaptesed pegol and lexapteptid pegol also suggest efficacy in the respective patient populations.

2008-09-01·Nucleic Acids Symposium Series

Physicochemical Stability of NOX-E36, a 40mer L-RNA (Spiegelmer) for Therapeutic Applications

Article

作者: Klaus Buchner ; Sven Klussmann ; Stefan Vonhoff ; Dirk Eulberg ; Christian Maasch

Spiegelmers are structured mirror-image oligonucleotides that are designed to bind and inhibit pharmacologically relevant target molecules. The synthesis and purification of mirror-image oligonucleotides is comparable to the manufacturing of standard oligonucleotides that consist of naturally configured nucleotides. Due to the use of the non-natural L-nucleotides in Spiegelmers, these oligonucleotides show an exceptional biostability. Further, they also display a high physicochemical stability in solution. These properties make them interesting substances for drug development.

1

项与 Emapticap pegol 相关的新闻（医药）

2024-07-22

·Business Wire

TME Pharma Announces Strategic Plan to Externalize and Monetize Second Clinical Stage Asset NOX-E36

BERLIN--( BUSINESS WIRE )-- TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces its plan to externalize and monetize the company's second clinical stage asset NOX-E36 – an L-stereoisomer RNA aptamer inhibiting the CCL2 chemokine. This decision leverages the compound’s potential, as shown by clinical and preclinical data, to safely address significant unmet medical needs in ophthalmic diseases impacted by fibrosis. The presence of the target of NOX-E36, CCL2, has been shown to predict early failure of glaucoma surgical intervention in patients and inhibition of the pathway targeted by NOX-E36 in preclinical models of glaucoma surgery prevents fibrosis thereby prolonging the success of the intervention 1 . NOX-E36 has already been administered to 175 clinical trial participants with an excellent safety and tolerability profile and showing activity on its target, already derisking a number of steps in early clinical development. Fibrosis is a significant cause of treatment failure or increased severity in many clinically important eye diseases 2 with unmet needs such as diabetic retinopathy (9.6 million cases in the US, of which 1.84 million vision-threatening 3 ), age-related macular degeneration (20 million cases in the US, of which 1.5 million vision-threatening 4 ), and primary open angle glaucoma (>3 million cases in the US 5 ). Click here to read the full press release 1 Chong (2017) Invest Ophthalmol Vis Sci 58:3432 & Chong (2010) Ophthalmology 117:2353 2 Sorenson (2024) Frontiers in Ophthalmology 2024 Vol. 4 3 Lundeen (2023) JAMA Ophthalmol. 2023;141(8):747-754 4 Rein (2022) JAMA Ophthalmol. 2022;140(12):1202-1208 5 US National Eye Institute Glaucoma Tables, Link

100 项与 Emapticap pegol 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病肾病	临床2期	捷克	TME Pharma NV	-
蛋白尿	临床1期	波兰	TME Pharma NV	2012-03-01
蛋白尿	临床1期	匈牙利	TME Pharma NV	2012-03-01
蛋白尿	临床1期	德国	TME Pharma NV	2012-03-01
蛋白尿	临床1期	捷克	TME Pharma NV	2012-03-01
蛋白尿	临床1期	罗马尼亚	TME Pharma NV	2012-03-01
糖尿病肾病	临床前	罗马尼亚	TME Pharma NV	-
糖尿病肾病	临床前	匈牙利	TME Pharma NV	-
糖尿病肾病	临床前	波兰	TME Pharma NV	-
糖尿病肾病	临床前	德国	TME Pharma NV	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01547897 (NOX-E36, ASN2012)	临床1期	糖尿病肾病 CCL2 (MCP-1)	-	NOX-E36	繭觸鬱簾製蓋簾鹹構憲(鏇鹽積顧遞遞壓鬱艱遞) = 構憲齋獵醖願衊積壓壓獵顧鏇積膚廠顧製糧鑰 (願壓壓齋糧繭鬱鹹鹹憲 ) 更多	积极	2012-10-30
				Placebo	繭觸鬱簾製蓋簾鹹構憲(鏇鹽積顧遞遞壓鬱艱遞) = 積艱顧選獵齋積顧製艱獵顧鏇積膚廠顧製糧鑰 (願壓壓齋糧繭鬱鹹鹹憲 )